1)Gomez-Reino JJ, Carmona L: BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observa-tional study of 488 patients over a four-year period. Arthritis Res Then 8(1): R29, 2006
2)Hyrich KL, Lunt M, Watson KD, et al: British Society for Rheu-matology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis:results from a large UK national cohort study. Arthritis Rheum. 56(1): 13-20,2007
3)Hjardem E,∅stergaard M, Pφdenphant J, et al: Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis. 66(9): 1184-9,2007
4)Laas K, Peltomaa R, Kautiainen H, et al: Clinical impact of switching from infliximab to etanercept in patients with rheuma-toid arthritis. Clin Rheumatol. 27(7):927-32,2008
5)Hyrich KL, Lunt M, Dixon WG, et al: BSR Biologics Register. Ef-fects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford). 47(7): 1000-5, Epub 2008